Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.

Chow VA, Gopal AK, Maloney DG, Turtle CJ, Smith SD, Ujjani CS, Shadman M, Cassaday RD, Till BG, Tseng YD, Warren EH, Shustov AR, Menon MP, Bhark S, Acharya UH, Mullane E, Hannan LM, Voutsinas JM, Gooley TA, Lynch RC.

Am J Hematol. 2019 May 6. doi: 10.1002/ajh.25505. [Epub ahead of print] No abstract available.

PMID:
31056762
2.

Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience.

Cooper JP, Khajaviyan S, Smith SD, Maloney DG, Shustov AR, Warren EH, Soma LA, Lynch RC, Ujjani C, Till B, Halpern AB, Gopal AK, Deeg HJ, Scott BL, Shadman M.

Clin Lymphoma Myeloma Leuk. 2019 Mar 11. pii: S2152-2650(19)30124-7. doi: 10.1016/j.clml.2019.03.003. [Epub ahead of print]

PMID:
30948330
3.

Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL.

Smith SD, Reddy P, Sokolova A, Chow VA, Lynch RC, Shadman MA, Till BG, Shustov AR, Warren EH, Ujjani CS, Menon MP, Tseng YD, Gopal AK.

Am J Hematol. 2019 Apr;94(4):E117-E116. doi: 10.1002/ajh.25411. Epub 2019 Feb 4. No abstract available.

PMID:
30663774
4.

Cytomegalovirus Exposure in the Elderly Does Not Reduce CD8 T Cell Repertoire Diversity.

Lindau P, Mukherjee R, Gutschow MV, Vignali M, Warren EH, Riddell SR, Makar KW, Turtle CJ, Robins HS.

J Immunol. 2019 Jan 15;202(2):476-483. doi: 10.4049/jimmunol.1800217. Epub 2018 Dec 12.

5.

Capacity building for hematologic malignancies in Uganda: a comprehensive research, training, and care program through the Uganda Cancer Institute-Fred Hutchinson Cancer Research Center collaboration.

Okello CD, Ddungu H, Omoding A, Towlerton AMH, Pitorak H, Maggard K, Ewart S, Phipps WT, Uldrick TS, Warren EH, Orem J.

Blood Adv. 2018 Nov 30;2(Suppl 1):8-10. doi: 10.1182/bloodadvances.2018GS111079. No abstract available.

6.

A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure.

Zeidan AM, Knaus HA, Robinson TM, Towlerton AMH, Warren EH, Zeidner JF, Blackford AL, Duffield AS, Rizzieri D, Frattini MG, Levy YM, Schroeder MA, Ferguson A, Sheldon KE, DeZern AE, Gojo I, Gore SD, Streicher H, Luznik L, Smith BD.

Clin Cancer Res. 2018 Aug 1;24(15):3519-3527. doi: 10.1158/1078-0432.CCR-17-3763. Epub 2018 May 1.

PMID:
29716921
7.

High-throughput sequencing of the B-cell receptor in African Burkitt lymphoma reveals clues to pathogenesis.

Lombardo KA, Coffey DG, Morales AJ, Carlson CS, Towlerton AMH, Gerdts SE, Nkrumah FK, Neequaye J, Biggar RJ, Orem J, Casper C, Mbulaiteye SM, Bhatia KG, Warren EH.

Blood Adv. 2017 Mar 21;1(9):535-544. doi: 10.1182/bloodadvances.2016000794. eCollection 2017 Mar 28.

8.

High-throughput sequencing reveals novel features of immunoglobulin gene rearrangements in Burkitt lymphoma.

Lombardo KA, Coffey DG, Morales AJ, Carlson CS, Towlerton AMH, Gerdts SE, Nkrumah FK, Neequaye J, Biggar RJ, Orem J, Casper C, Mbulaiteye SM, Bhatia KG, Warren EH.

Blood Adv. 2017 Jul 3;1(16):1261-1262. doi: 10.1182/bloodadvances.2017008060. eCollection 2017 Jul 11. No abstract available.

9.

Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer.

Qin A, Street L, Cease K, Viglianti BL, Warren EH, Zhao L, Ramnath N.

Clin Lung Cancer. 2017 Sep;18(5):559-564. doi: 10.1016/j.cllc.2017.01.012. Epub 2017 Feb 9.

10.

Validation of single nucleotide polymorphisms in invasive aspergillosis following hematopoietic cell transplantation.

Fisher CE, Hohl TM, Fan W, Storer BE, Levine DM, Zhao LP, Martin PJ, Warren EH, Boeckh M, Hansen JA.

Blood. 2017 May 11;129(19):2693-2701. doi: 10.1182/blood-2016-10-743294. Epub 2017 Mar 7.

11.

Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide.

Kanakry CG, Bakoyannis G, Perkins SM, McCurdy SR, Vulic A, Warren EH, Daguindau E, Olmsted T, Mumaw C, Towlerton AMH, Cooke KR, O'Donnell PV, Symons HJ, Paczesny S, Luznik L.

Haematologica. 2017 May;102(5):932-940. doi: 10.3324/haematol.2016.152322. Epub 2017 Jan 25.

12.

Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease.

Martin PJ, Levine DM, Storer BE, Warren EH, Zheng X, Nelson SC, Smith AG, Mortensen BK, Hansen JA.

Blood. 2017 Feb 9;129(6):791-798. doi: 10.1182/blood-2016-09-737700. Epub 2016 Nov 21.

13.

Replication of associations between genetic polymorphisms and chronic graft-versus-host disease.

Martin PJ, Fan W, Storer BE, Levine DM, Zhao LP, Warren EH, Flowers ME, Lee SJ, Carpenter PA, Boeckh M, Hingorani S, Yan L, Hu Q, Preus L, Liu S, Spellman S, Zhu X, Pasquini M, McCarthy P, Stram D, Sheng X, Pooler L, Haiman CA, Sucheston-Campbell L, Hahn T, Hansen JA.

Blood. 2016 Nov 17;128(20):2450-2456. Epub 2016 Oct 6.

14.

Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer.

Qin A, Coffey DG, Warren EH, Ramnath N.

Cancer Med. 2016 Sep;5(9):2567-78. doi: 10.1002/cam4.819. Epub 2016 Jul 15. Review.

15.

Genetic risk factors for sclerotic graft-versus-host disease.

Inamoto Y, Martin PJ, Flowers ME, Lee SJ, Carpenter PA, Warren EH, Geraghty DE, Lee N, Boeckh MJ, Storer BE, Levine DM, Fan W, Zhao LP, Hansen JA.

Blood. 2016 Sep 15;128(11):1516-24. doi: 10.1182/blood-2016-05-715342. Epub 2016 Jun 16.

16.

Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide.

Kanakry CG, Coffey DG, Towlerton AM, Vulic A, Storer BE, Chou J, Yeung CC, Gocke CD, Robins HS, O'Donnell PV, Luznik L, Warren EH.

JCI Insight. 2016;1(5). pii: e86252. Epub 2016 Apr 21.

17.

Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans.

Nakasone H, Tian L, Sahaf B, Kawase T, Schoenrock K, Perloff S, Ryan CE, Paul J, Popli R, Wu F, Otani JM, Coller J, Warren EH 3rd, Miklos DB.

Blood. 2015 May 14;125(20):3193-201. doi: 10.1182/blood-2014-11-613323. Epub 2015 Mar 12.

18.

Dynamics of the cytotoxic T cell response to a model of acute viral infection.

DeWitt WS, Emerson RO, Lindau P, Vignali M, Snyder TM, Desmarais C, Sanders C, Utsugi H, Warren EH, McElrath J, Makar KW, Wald A, Robins HS.

J Virol. 2015 Apr;89(8):4517-26. doi: 10.1128/JVI.03474-14. Epub 2015 Feb 4.

19.

Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells.

Pollack SM, Jones RL, Farrar EA, Lai IP, Lee SM, Cao J, Pillarisetty VG, Hoch BL, Gullett A, Bleakley M, Conrad EU 3rd, Eary JF, Shibuya KC, Warren EH, Carstens JN, Heimfeld S, Riddell SR, Yee C.

J Immunother Cancer. 2014 Oct 14;2(1):36. doi: 10.1186/s40425-014-0036-y. eCollection 2014.

20.

Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC.

Klippel ZK, Chou J, Towlerton AM, Voong LN, Robbins P, Bensinger WI, Warren EH.

Gene Ther. 2014 Mar;21(3):337-42. doi: 10.1038/gt.2013.87. Epub 2014 Jan 23.

21.

Phenotypic and transcriptional fidelity of patient-derived colon cancer xenografts in immune-deficient mice.

Chou J, Fitzgibbon MP, Mortales CL, Towlerton AM, Upton MP, Yeung RS, McIntosh MW, Warren EH.

PLoS One. 2013 Nov 20;8(11):e79874. doi: 10.1371/journal.pone.0079874. eCollection 2013.

22.

HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway.

Goodridge JP, Lee N, Burian A, Pyo CW, Tykodi SS, Warren EH, Yee C, Riddell SR, Geraghty DE.

J Immunol. 2013 Aug 15;191(4):1567-77. doi: 10.4049/jimmunol.1300080. Epub 2013 Jul 12.

23.

Toward eliminating HLA class I expression to generate universal cells from allogeneic donors.

Torikai H, Reik A, Soldner F, Warren EH, Yuen C, Zhou Y, Crossland DL, Huls H, Littman N, Zhang Z, Tykodi SS, Kebriaei P, Lee DA, Miller JC, Rebar EJ, Holmes MC, Jaenisch R, Champlin RE, Gregory PD, Cooper LJ.

Blood. 2013 Aug 22;122(8):1341-9. doi: 10.1182/blood-2013-03-478255. Epub 2013 Jun 5.

24.

High-throughput sequencing of B- and T-lymphocyte antigen receptors in hematology.

Warren EH, Matsen FA 4th, Chou J.

Blood. 2013 Jul 4;122(1):19-22. doi: 10.1182/blood-2013-03-453142. Epub 2013 May 8.

25.

Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies.

Warren EH, Deeg HJ.

Tissue Antigens. 2013 Apr;81(4):183-93. doi: 10.1111/tan.12090. Review.

26.

Diversifying the MHC peptide portfolio.

Warren EH.

Blood. 2012 Oct 18;120(16):3165-7. doi: 10.1182/blood-2012-08-451484. No abstract available.

27.

CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft model.

Tykodi SS, Satoh S, Deming JD, Chou J, Harrop R, Warren EH.

J Immunother. 2012 Sep;35(7):523-33. doi: 10.1097/CJI.0b013e318261d630.

28.

Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT.

Warren EH, Zhang XC, Li S, Fan W, Storer BE, Chien JW, Boeckh MJ, Zhao LP, Martin PJ, Hansen JA.

Blood. 2012 Oct 4;120(14):2796-806. doi: 10.1182/blood-2012-04-347286. Epub 2012 Aug 2. Review.

29.

Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen.

Ochsenreither S, Majeti R, Schmitt T, Stirewalt D, Keilholz U, Loeb KR, Wood B, Choi YE, Bleakley M, Warren EH, Hudecek M, Akatsuka Y, Weissman IL, Greenberg PD.

Blood. 2012 Jun 7;119(23):5492-501. doi: 10.1182/blood-2011-07-365890. Epub 2012 Apr 23.

30.

Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer.

Chou J, Voong LN, Mortales CL, Towlerton AM, Pollack SM, Chen X, Yee C, Robbins PF, Warren EH.

J Immunother. 2012 Feb-Mar;35(2):131-41. doi: 10.1097/CJI.0b013e31824300c7.

31.

Evaluation of published single nucleotide polymorphisms associated with acute GVHD.

Chien JW, Zhang XC, Fan W, Wang H, Zhao LP, Martin PJ, Storer BE, Boeckh M, Warren EH, Hansen JA.

Blood. 2012 May 31;119(22):5311-9. doi: 10.1182/blood-2011-09-371153. Epub 2012 Jan 26. Review.

32.

Applications of next-generation sequencing to blood and marrow transplantation.

Chapman M, Warren EH 3rd, Wu CJ.

Biol Blood Marrow Transplant. 2012 Jan;18(1 Suppl):S151-60. doi: 10.1016/j.bbmt.2011.11.011. Review.

33.

Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation.

Inamoto Y, Flowers ME, Lee SJ, Carpenter PA, Warren EH, Deeg HJ, Storb RF, Appelbaum FR, Storer BE, Martin PJ.

Blood. 2011 Jul 14;118(2):456-63. doi: 10.1182/blood-2011-01-330217. Epub 2011 Jun 1.

34.

Blazing a trail in T-cell recognition.

Warren EH.

Blood. 2011 May 5;117(18):4681-2. doi: 10.1182/blood-2011-03-337642. No abstract available.

35.

Activation and expansion of CD8(+) T effector cells in patients with chronic graft-versus-host disease.

Grogan BM, Tabellini L, Storer B, Bumgarner TE, Astigarraga CC, Flowers ME, Lee SJ, Martin PJ, Warren EH, Hansen JA.

Biol Blood Marrow Transplant. 2011 Aug;17(8):1121-32. doi: 10.1016/j.bbmt.2011.03.007. Epub 2011 Mar 24.

36.

Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after.

Tykodi SS, Sandmaier BM, Warren EH, Thompson JA.

Expert Opin Biol Ther. 2011 Jun;11(6):763-73. doi: 10.1517/14712598.2011.566855. Epub 2011 Mar 21. Review.

37.

Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria.

Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, Pereira SE, Nash RA, Mielcarek M, Fero ML, Warren EH, Sanders JE, Storb RF, Appelbaum FR, Storer BE, Martin PJ.

Blood. 2011 Mar 17;117(11):3214-9. doi: 10.1182/blood-2010-08-302109. Epub 2011 Jan 24.

38.

A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation.

Inamoto Y, Fefer A, Sandmaier BM, Gooley TA, Warren EH, Petersdorf SH, Sanders JE, Storb RF, Appelbaum FR, Martin PJ, Flowers ME.

Biol Blood Marrow Transplant. 2011 Sep;17(9):1308-15. doi: 10.1016/j.bbmt.2011.01.004. Epub 2011 Jan 11.

39.

Graft versus leukemia reactivity after allogeneic stem cell transplantation.

Falkenburg JH, Warren EH.

Biol Blood Marrow Transplant. 2011 Jan;17(1 Suppl):S33-8. doi: 10.1016/j.bbmt.2010.11.009. Review. No abstract available.

40.

Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities.

Eissa H, Gooley TA, Sorror ML, Nguyen F, Scott BL, Doney K, Loeb KR, Martin PJ, Pagel JM, Radich JP, Sandmaier BM, Warren EH, Storb R, Appelbaum FR, Deeg HJ.

Biol Blood Marrow Transplant. 2011 Jun;17(6):908-15. doi: 10.1016/j.bbmt.2010.09.018. Epub 2010 Oct 6.

41.

Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation.

Hansen JA, Chien JW, Warren EH, Zhao LP, Martin PJ.

Curr Opin Hematol. 2010 Nov;17(6):483-92. doi: 10.1097/MOH.0b013e32833eb770. Review.

42.

Overlap and effective size of the human CD8+ T cell receptor repertoire.

Robins HS, Srivastava SK, Campregher PV, Turtle CJ, Andriesen J, Riddell SR, Carlson CS, Warren EH.

Sci Transl Med. 2010 Sep 1;2(47):47ra64. doi: 10.1126/scitranslmed.3001442.

43.

Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells.

Bleakley M, Otterud BE, Richardt JL, Mollerup AD, Hudecek M, Nishida T, Chaney CN, Warren EH, Leppert MF, Riddell SR.

Blood. 2010 Jun 10;115(23):4923-33. doi: 10.1182/blood-2009-12-260539. Epub 2010 Mar 4.

44.

NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.

Miller JS, Warren EH, van den Brink MR, Ritz J, Shlomchik WD, Murphy WJ, Barrett AJ, Kolb HJ, Giralt S, Bishop MR, Blazar BR, Falkenburg JH.

Biol Blood Marrow Transplant. 2010 May;16(5):565-86. doi: 10.1016/j.bbmt.2010.02.005. Epub 2010 Feb 10.

45.

Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens.

Warren EH, Fujii N, Akatsuka Y, Chaney CN, Mito JK, Loeb KR, Gooley TA, Brown ML, Koo KK, Rosinski KV, Ogawa S, Matsubara A, Appelbaum FR, Riddell SR.

Blood. 2010 May 13;115(19):3869-78. doi: 10.1182/blood-2009-10-248997. Epub 2010 Jan 13.

46.

Abnormalities of the alphabeta T-cell receptor repertoire in advanced myelodysplastic syndrome.

Campregher PV, Srivastava SK, Deeg HJ, Robins HS, Warren EH.

Exp Hematol. 2010 Mar;38(3):202-12. doi: 10.1016/j.exphem.2009.12.004. Epub 2009 Dec 24.

47.

Combining allogeneic immunotherapy with an mTOR inhibitor for advanced renal cell carcinoma.

Tykodi SS, Voong LN, Warren EH.

Bone Marrow Transplant. 2010 Aug;45(8):1360-2. doi: 10.1038/bmt.2009.338. Epub 2009 Dec 7. No abstract available.

48.

Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease.

McCarroll SA, Bradner JE, Turpeinen H, Volin L, Martin PJ, Chilewski SD, Antin JH, Lee SJ, Ruutu T, Storer B, Warren EH, Zhang B, Zhao LP, Ginsburg D, Soiffer RJ, Partanen J, Hansen JA, Ritz J, Palotie A, Altshuler D.

Nat Genet. 2009 Dec;41(12):1341-4. doi: 10.1038/ng.490.

49.

Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells.

Robins HS, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, Kahsai O, Riddell SR, Warren EH, Carlson CS.

Blood. 2009 Nov 5;114(19):4099-107. doi: 10.1182/blood-2009-04-217604. Epub 2009 Aug 25.

50.

Genetic risk for colitis-associated colorectal cancer.

Warren EH.

Gut. 2009 Sep;58(9):1177-9. doi: 10.1136/gut.2009.181206. No abstract available.

PMID:
19671548

Supplemental Content

Loading ...
Support Center